BNP Paribas Financial Markets Purchases 84,776 Shares of AtriCure, Inc. (NASDAQ:ATRC)

BNP Paribas Financial Markets lifted its position in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 676.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 97,310 shares of the medical device company's stock after acquiring an additional 84,776 shares during the period. BNP Paribas Financial Markets owned approximately 0.20% of AtriCure worth $2,974,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Silver Oak Securities Incorporated bought a new stake in shares of AtriCure during the 4th quarter worth approximately $220,000. JPMorgan Chase & Co. increased its position in AtriCure by 43.1% during the 4th quarter. JPMorgan Chase & Co. now owns 365,183 shares of the medical device company's stock worth $11,160,000 after purchasing an additional 110,039 shares in the last quarter. Calamos Advisors LLC increased its position in AtriCure by 27.9% during the 4th quarter. Calamos Advisors LLC now owns 110,671 shares of the medical device company's stock worth $3,382,000 after purchasing an additional 24,147 shares in the last quarter. M&T Bank Corp acquired a new position in AtriCure during the 4th quarter worth approximately $208,000. Finally, Sei Investments Co. increased its position in AtriCure by 6.1% during the 4th quarter. Sei Investments Co. now owns 107,290 shares of the medical device company's stock worth $3,279,000 after purchasing an additional 6,152 shares in the last quarter. Institutional investors own 99.11% of the company's stock.

Insider Transactions at AtriCure

In other news, Director Karen Prange sold 6,100 shares of the stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total transaction of $232,532.00. Following the completion of the sale, the director now directly owns 17,828 shares in the company, valued at $679,603.36. This represents a 25.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 3.50% of the stock is currently owned by corporate insiders.

AtriCure Price Performance

ATRC stock opened at $32.30 on Friday. The company has a fifty day moving average price of $32.43 and a 200-day moving average price of $34.83. The company has a market capitalization of $1.60 billion, a P/E ratio of -34.00 and a beta of 1.57. AtriCure, Inc. has a 52-week low of $18.94 and a 52-week high of $43.11. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.62 and a current ratio of 3.65.

AtriCure (NASDAQ:ATRC - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The medical device company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.11. AtriCure had a negative net margin of 9.61% and a negative return on equity of 6.80%. The firm had revenue of $123.62 million during the quarter, compared to the consensus estimate of $122.92 million. During the same quarter last year, the firm earned ($0.28) earnings per share. The company's revenue for the quarter was up 13.5% on a year-over-year basis. As a group, equities analysts expect that AtriCure, Inc. will post -0.6 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on ATRC shares. JPMorgan Chase & Co. lowered their price objective on shares of AtriCure from $51.00 to $46.00 and set an "overweight" rating for the company in a research report on Thursday, March 27th. BTIG Research reiterated a "buy" rating on shares of AtriCure in a research report on Thursday, March 27th. Oppenheimer upped their price objective on shares of AtriCure from $36.00 to $45.00 and gave the stock an "outperform" rating in a research report on Thursday, February 13th. Needham & Company LLC lowered their price objective on shares of AtriCure from $51.00 to $44.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. Finally, UBS Group lowered their price objective on shares of AtriCure from $60.00 to $58.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, AtriCure presently has a consensus rating of "Moderate Buy" and a consensus price target of $50.67.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.

Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure, Inc. (NASDAQ:ATRC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.